Chairs: Ira Jacobson and Maura Dandri

• 10:30 a.m. - 10:50 a.m. Gene and Epigenome editing: what is the current knowledge on efficacy and risks? - Fabien Zoulim
• 10:50 a.m. - 11:10 a.m. Advances in HDV treatment: Bulevirtide vs. mAb vs. small molecule, is there a front runner? - Pietro Lampertico
• 11:10 a.m. - 11:30 a.m. Immune dysfunction vs. exhaustion - splitting hairs or real impact on immunotherapy - Georg Lauer
• 11:30 a.m. - 12:00 p.m. Discussion